Page last updated: 2024-11-13

mm 36

Description

difamilast: selective phosphodiesterase type‐4 (PDE4) inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Synonym
n-[2-(4-difluoromethoxy-3-isopropoxyphenyl)oxazol-4-ylmethyl]-2-ethoxybenzamide
SCHEMBL4275421
n-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide
difamilast
937782-05-3
benzamide, n-((2-(4-(difluoromethoxy)-3-(1-methylethoxy)phenyl)-4-oxazolyl)methyl)-2-ethoxy-
difamilast [jan]
opa-15406
difamilast [usan]
difamilast [who-dd]
difamilast [inn]
T3U32GLJ0F ,
n-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)-2-ethoxybenzamide
example 352 [wo2007058338]
gtpl9776
n-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
moizerto
usre46792, 352
bdbm389126
n-((2-(4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl)-1,3-oxazol-4-yl)methyl)-2-ethoxybenzamide
unii-t3u32glj0f
mm36
DB14987
CHEMBL3989968
D11314
difamilast (jan/usan)
MS-28058
benzamide, n-[[2-[4-(difluoromethoxy)-3-(1-methylethoxy)phenyl]-4-oxazolyl]methyl]-2-ethoxy-
HY-109085
GLXC-26792
AKOS040748251
EX-A7792

Excerpt	Reference	Relevance
" No deaths or serious treatment-emergent adverse events were reported; all treatment-emergent adverse events were mild or moderate in severity."	( Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic derm Abe, Y; Baba, N; Oshiden, K; Saeki, H; Tsubouchi, H, 2020)	0.56
" No difference in treatment-related adverse events was identified."	( Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Chang, SP; Chao, CM; Lai, CC; Lan, SH; Lu, LC, 2022)	0.72
"This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD."	( Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Chang, SP; Chao, CM; Lai, CC; Lan, SH; Lu, LC, 2022)	0.72

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	7 (100.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (42.86%)	5.53%
Reviews	2 (28.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2 (28.57%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.6	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Eczema, Atopic [description not available]	0	8.43	7	3
Dermatitis, Eczematous [description not available]	0	6.89	3	2
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	1	10.43	7	3
Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).	0	6.89	3	2
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	3.8	1	1
Allergic Contact Dermatitis [description not available]	0	2.6	1	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	0	2.6	1	0